# Semaglutide Side Effects: What the Research Literature Reports > Semaglutide side effects documented in STEP, SUSTAIN, and PIONEER clinical trials: GI adverse events, thyroid C-cell warning, hair loss, lean mass loss, drug interactions, and post-marketing signals. ## Safety profile of Semaglutide across clinical programs Semaglutide's safety profile is well-characterized across the STEP and SUSTAIN programs. Pooled Phase 3 data reports most adverse events as GI in nature and dose-dependent. Serious adverse event rates are comparable to placebo except for GI events requiring medical attention in a small percentage of participants [14]. Most common adverse events: nausea (14–58% across trials), diarrhea (~30%), constipation, vomiting — dose-dependent, highest during escalation, declining at maintenance dose [13]. Post-marketing FAERS (2022–2023): disproportionate reporting signals for intestinal obstruction, cholecystitis, and pancreatic cancer — causality not established [18]. **What are the side effects of Semaglutide?** GI effects (nausea 14–58%, diarrhea ~30%, constipation, vomiting) most common, typically dose-dependent and transient during escalation. Rare but serious: pancreatitis (HR 1.05 pooled), thyroid C-cell concerns from rodent data, retinopathy risk in SUSTAIN-6, aspiration risk under anesthesia [13, 14]. ## Mechanisms of nausea in Semaglutide studies GLP-1 receptor activation in the area postrema (brainstem chemoreceptor trigger zone, lacks blood-brain barrier) and delayed gastric emptying are the two proposed mechanisms [13]. Nausea peaks at higher escalation doses, diminishes at maintenance. STEP 1: nausea declining from ~44% during escalation to ~20% at maintenance. **Why does Semaglutide cause nausea?** GLP-1R activation in the area postrema (vomiting center) and delayed gastric emptying; dose-dependent, most pronounced during dose escalation [13]. ## Serious adverse events reported in Semaglutide research Thyroid C-cell tumors: FDA box warning based exclusively on rodent data. GLP-1R expression in human thyroid is marginal compared to rodent thyroid; clinical trial data has not established increased thyroid cancer risk in humans. Pancreatitis HR 1.05 — no statistically significant increase versus placebo [14]. Retinopathy: SUSTAIN-6 documented significantly elevated retinopathy complications in the semaglutide arm — proposed mechanism is rapid glycemic improvement in previously poorly controlled patients [6]. Post-marketing FAERS signals: intestinal obstruction, cholecystitis, pancreatic cancer disproportionate reporting signals (2022–2023). Causality not established; prospective evaluation ongoing [18]. **What are the dangers of taking Semaglutide?** Thyroid C-cell tumor risk (rodent data at suprapharmacological doses), pancreatitis HR 1.05, aspiration risk during anesthesia from gastroparesis [14]. ## Semaglutide and hair loss: what trial data shows Alopecia reported in 3.3% of clinical trial participants versus 1.4% placebo. Relative risk 2.38 (95% CI 1.41–4.0). Participants achieving >20% weight loss: 5.3% alopecia versus 2.5% [20]. Proposed mechanism: telogen effluvium from rapid weight loss-induced physiological stress. Not listed as a primary adverse event in Phase 3 data [20]. ## Lean mass changes in Semaglutide-treated study participants STEP 1 DEXA substudy (N=140): fat mass decreased 19.3% total; visceral adipose tissue decreased 27.4%. Absolute lean body mass also decreased — 9.7% over 68 weeks. Lean-to-fat mass ratio improved by 0.23 overall [15]. **What is the downside of Semaglutide?** Absolute lean mass loss (-9.7% in STEP 1 DEXA substudy), weight regain after discontinuation (mean 11.6 percentage points within one year [3]), high cost and access barriers. ## Drug interactions documented in Semaglutide pharmacology Dedicated interaction study with metformin, warfarin, atorvastatin, and digoxin [11]: no clinically significant AUC effects for any of the four agents. Atorvastatin Cmax reduced ~38% but AUC unchanged. Insulin secretagogues increase hypoglycemia risk via pharmacodynamic (additive) mechanism. ## Semaglutide and alcohol: observations from research Preclinical: semaglutide reduced alcohol consumption in rat models and blunted nucleus accumbens dopamine release via GLP-1R activation in VTA [17]. Observational human data: GLP-1RA use linked with ~50% reduced AUD risk in type 2 diabetes patients [19]. Multiple prospective RCTs ongoing. ## References [3] Wilding JPH, et al. STEP 1 trial extension. Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14725 [6] Marso SP, et al. SUSTAIN-6. N Engl J Med. 2016;375(19):1834-1844. DOI: 10.1056/NEJMoa1607141 [11] Tamayo-Trujillo R, et al. Molecular mechanisms of semaglutide. Front Nutr. 2024;11:1398059. DOI: 10.3389/fnut.2024.1398059 [13] Papakonstantinou I, et al. Spotlight on Mechanism. Curr Issues Mol Biol. 2024;46(12):13632-13656. DOI: 10.3390/cimb46120872 [14] Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol. 2021;12:645563. DOI: 10.3389/fendo.2021.645563 [15] Wilding JPH, et al. Impact on Body Composition, STEP 1 exploratory. J Endocr Soc. 2021. DOI: 10.1210/jendso/bvab048.030 [17] Chuong V, et al. Semaglutide reduces alcohol drinking. JCI Insight. 2023;8(12):e170671. DOI: 10.1172/jci.insight.170671 [18] Du Y, et al. Post-marketing pharmacovigilance analysis. J Diabetes Investig. 2024;15(11):1601-1610. DOI: 10.1111/jdi.14229 [19] Klausen MK, et al. GLP-1 Receptor Agonists in Alcohol Use Disorder. Basic Clin Pharmacol Toxicol. 2025. DOI: 10.1111/bcpt.70004 [20] Various authors. Alopecia and Semaglutide. Dermatol Ther. 2025. PMC11909624 --- A trial-by-trial weighing of the semaglutide evidence record — STEP, SUSTAIN, SELECT, PIONEER — reported plainly, cited fully, and sold by no one.